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A two-step resin based approach to reveal
survivin-selective fluorescent probes†
Andrew J. Ambrose, a Nhan T. Pham, b Jared Sivinski, a Larissa Guimarães, ‡ac
Niloufar Mollasalehi, a Paula Jimenez, d Maria A. Abad, e
A. Arockia Jeyaprakash, e Steven Shave, b Letı́cia V. Costa-Lotufo, c
James J. La Clair, *f Manfred Auer *b and Eli Chapman *a
The identification of modulators for proteins without assayable
biochemical activity remains a challenge in chemical biology.
The presented approach adapts a high-throughput fluorescence
binding assay and functional chromatography, two protein-resin
technologies, enabling the discovery and isolation of fluorescent
natural product probes that target proteins independently of bio-
chemical function. The resulting probes also suggest targetable
pockets for lead discovery. Using human survivin as a model, we
demonstrate this method with the discovery of members of the
prodiginine family as fluorescent probes to the cancer target survivin.
Nature contains a remarkable collection of spectroscopically
active materials, including fluorescent compounds.1 Although
many fluorescent dyes2 are derived from natural scaffolds,3 the
translation of fluorescent natural products into biochemical
probes remains particularly slow, with epicocconone providing
a rare but excellent example.4 This disparity arises in part due
to a disconnect that exists between the chemical and biological
aspects of probe discovery. Here, we demonstrate how a two-
resin system can function as a discovery platform for targeted
proteins not amenable to high-throughput activity based
screening. As shown in steps 1–4 of Scheme 1, this system
applies a protein coated non-porous resin to screen and prior-
itize extracts. The prioritized extracts are then forwarded to a
second, porous protein coated resin, which is used to isolate
the active molecule from a mixture (steps 5–10, Scheme 1).
A series of studies including those by our team (Chapman
and La Clair)5 demonstrated that one can employ resin-bound
protein as a vehicle to enrich for molecules that bind to a
protein of interest (target protein). Using a complex mixture of
molecules, this method represents a form of reversed-affinity or
‘functional’ chromatography (FC).6 In our studies, we demon-
strated this process by identifying ligands to three different
binding pockets on the ATPase p97; two of these molecules did
not target p97’s ATP-binding pocket, and could have been
missed by conventional enzymatic screening.5
Parallel efforts led by the Auer laboratory developed microbead
based screening technologies, initially for combinatorial chemistry7
and later for difficult enzymatic reactions8 and protein binding.9
Bead based scanning assays with confocal imaging readout, so
called CONA assays, offer a series of advantages: they are
miniaturized, versatile, extremely sensitive, multiplexed, quan-
titative, fast and can be automated.
Herein, we united efforts to explore a combination of CONA
and FC to rapidly identify fluorescent natural product probes to
an important oncology target with no known enzymatic func-
tion, the inhibitor of apoptosis (IAP), survivin. Fluorescent
natural product probes offer two major advantages: (a) high-
affinity, selective probes offer a means to study proteins in a
cellular context by looking at subcellular localization while
simultaneously studying the effects of a rapid inhibition of
protein function; and (b) fluorescent probes, even with modest
affinity and selective, provide a means to develop a fluorescent
polarization assay that is amenable to high throughput compe-
titive screening.
Survivin is the smallest member of the IAP family of proteins,
and the first among the IAPs shown to have a function outside of
caspase inhibition.10 In fact, survivin is likely incapable of
directly inhibiting caspase activity, but instead binds a series
of other proteins to carry out this anti-apoptotic function in vivo.
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In addition to these roles, survivin regulates signal transduc-
tion pathways associated with cancer.11 While suggested as a
therapeutic target,12 drugging survivin or related IAPs has yet to
reach fruition, and presents a drug discovery challenge we felt
our strategy would be particularly suited to facilitate.13 Here, we
develop an agnostic method to identify fluorescent ligands to
survivin. The hope is that these tools will not only enable high-
throughput screening efforts for IAP antagonists but also allow
for untangling the complex physiologic actions associated with
IAPs, including survivin.
Our studies began by screening a panel of 548 fluorescent
marine microbial and sponge extracts to discover fluorescent
survivin binders. We began by loading His6-tagged full length
survivin to homogenous size Ni2+NTA agarose beads (step 1,
Scheme 1; see Fig. S1, ESI† for survivin purification and purity
analysis). The resulting resins were then presented with the
fluorescent extracts (step 2, Scheme 1) and evaluated for fluores-
cence using CONA and image analysis (BREAD).8,9 Two hits were
observed as given by the appearance of fluorescent halos. The
brightest (strong halos in Fig. 1), an extract from Actinomadura sp.
BRA 177 at 200 (25 mg mL1) and 1000 (5 mg mL1) dilutions
from a DMSO stock generated a dose-dependent fluorescent
response on the Ni2+NTA-resin with His6-survivin, but not on
resins without survivin (steps 3–4, Scheme 1).
We then turned to the second or FC resin to isolate the active
fluorescent material. Beginning with step 5 (Scheme 1), the FC
resin was prepared by covalently attaching His6-survivin to
Affi-Gel 10 resin. Using established methods,5 we were able to
prepare a resin with 5 mg mL1 (310 mM) of His6-survivin.
A 300 mL aliquot of FC resin was then incubated with 1.6 mL of
10 mg mL1 BRA 177 extract in pH 7.2 PBS containing 5%
DMSO. After shaking at 4 1C (step 6, Scheme 1) for 12 h, the
resin was washed with 1.6 mL of PBS (step 7, Scheme 1) and
the bound materials were eluted by denaturing the protein
in 200 mL of ethanol (EtOH) (step 8, Scheme 1). We then
confirmed we captured the desired fluorescent material by
screening the survivin-bound fractions from the FC resin with
the CONA resin (steps 3–4, Scheme 1). As shown in Fig. 2b, we
observed the same fluorescent response from the affinity-
purified fraction as compared to controls (Fig. 2a).
Using a 1.7 mm probe for microscale NMR analysis, we were
able to obtain a 1H-NMR spectrum from the affinity-isolated
fraction evaluated in Fig. 2b. This spectrum contained aromatic
Scheme 1 Target protein-guided hit prioritization and probe identifi-
cation. Two different resins, a scanning confocal microscopy (CONA) resin
and a functional chromatographic (FC) resin, are applied to screen extracts
(a–d) for protein binders and isolate them. (step 1) The process begins by
preparing Ni2+NTA resin loaded with a target protein (CONA resin). (step 2)
The resulting CONA resin is presented with natural product extracts (a–d).
(step 3) Compounds in target-protein active extracts bind to the target on
the surface of the CONA resin. Upon excitation, fluorescent natural
products on the CONA resin fluoresce as shown by a halo (green).
(step 4) Extracts (a–d) are then scored based on the level of fluorescence
observed on the CONA resin surface. (step 5) A second resin (FC resin) is
prepared by covalently attaching the target protein to a porous resin
(Affi-Gel 10 or 15). (step 6) Prioritized extracts from the CONA screen
(steps 1–5) are then presented to the FC resin. (step 7) This resin is then
washed with buffer to remove non-specific compounds. (step 8) The
bound materials are eluted by denaturing the protein on the FC resin with
an organic solvent (EtOH). (step 9) The resulting EtOH fractions containing
hits are evaluated for fluorescence, and non-fluorescent hits are excluded
(non-dyes). (step 9) The fluorescent hits are evaluated by capillary NMR,
and if sufficiently pure are used as is. If not they are purified by HPLC or
flash chromatography. (step 10) The binding of each candidate probe (hit)
to its target protein is then validated.
Fig. 1 Confocal fluorescence scanning images arising from the incuba-
tion of unloaded Ni2+NTA resin or survivin-loaded CONA resin (Scheme 1)
with 200 pmol (200 mL of 1 mM stock) of His6-survivin with extracts BRA
177 and X0192. (a) Brightfield (BF) and fluorescence (FL) images are shown
for experiments using Ni2+NTA resin without survivin. (b) BF and FL images
are shown for experiments with CONA resin. Two extract dilutions 1000
(high dilution) and 200 (low dilution) were compared to show fluores-
cence correlates with concentration. Fluorescence (FL) in both panels
was collected by excitation at 561 nm and collecting emission at 585 nm.
Fluorescence was not observed in control experiments using a non IAP
protein, NusB/E (see Fig. S2, ESI†).
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protons between 5.5–7.5 ppm, typical of what one would antici-
pate from a fluorescent compound (Fig. 3a). We were then able to
use NMR-guided flash chromatography to isolate 3.1 mg of pure
cyclononylprodigiosin (1) from the BRA 177 extract. The assign-
ment of 1 was further validated by high-resolution mass spectro-
metry (HRMS) returning m/z for C23H30N3O, [M + H]
+ calculated:
364.2383; found: 364.2382. Full characterization of this extract
was then conducted.14 While 1 was clearly evident in the FC
resin-bound fraction (Fig. 3b), we also observed unsaturated
fatty acid signatures (*, Fig. 3a) within this fraction, a common
non-specific protein binder found during FC.5
Overall, the NMR spectrum from 1 (Fig. 3b) displayed
excellent correlation with that observed in the FC-enriched
survivin-bound fraction (Fig. 3a) and gave a positive CONA
result.5 Here, the union between CONA for hit screening and
FC for compound enrichment and purification enabled rapid
hit identification (CONA) and isolation (FC).
As a further confirmation of the power of this CONA–FC
coupled approach (Scheme 1), we examined a second sample,
X0192, a 1 : 1 EtOAc/hexanes fraction from an extract of the
sponge Xestospongia testudinaria, that displayed weak fluores-
cence in the parent screen with the CONA resin (Fig. 1b) versus
controls (Fig. 1a). Purification with the FC resin using the same
methods as used for the BRA 177 extract, provided comparable
fluorescence from the affinity-selected fraction (Fig. 2d) versus
controls (Fig. 2b). Microscale NMR analysis again returned a
1H NMR spectrum that contained aromatic residues from the
FC resin-bound fraction (Fig. 4b). Remarkably, this compound
was only observed as a trace material in the X0192 fraction
(Fig. 4a). Analysis of these data along with 1.2 mg of pure
material purified by flash chromatography indicated that 2 was
prodigiosin. This observation was further supported by HRMS
data with an m/z for C20H26N3O, [M + H]
+ calculated: 324.1998;
found: 324.1987.
We then turned our attention to validate the binding of 1
and 2 to survivin in solution. We began by characterizing the
fluorescence of 1 and 2 (Fig. 5a) in 20 mM HEPES, pH 7.5,
100 mM NaCl containing 2% DMSO. Absorption and emission
wavelengths were determined to be lex 534 nm and lem 556 nm
Fig. 2 Confocal fluorescence scanning images of CONA resins presented
with FC resin-bound fractions from the BRA 177 extract or X0192 fraction.
(a) Control experiments using Ni2+NTA resin and the CONA resin containing
200 pmol (200 mL of 1 mM stock) His6-survivin. (b) Experiments using control
Ni2+NTA resin and CONA resin containing 200 pmol survivin in the presence
of 5 mM lead 1 from the FC resin bound extract of BRA 177 (see NMR of this
fraction in Fig. 3a). (c) Control experiments using Ni2+NTA resin and CONA
resin containing 200 pmol survivin. (d) Experiments using control Ni2+NTA
resin and CONA resin containing 200 pmol survivin in the presence of 5 mM
2 from the FC resin bound extract of X0192 (see NMR of this fraction in
Fig. 4b). BF indicates bright field images. FL in both panels was collected by
excitation at 561 nm and collecting emission at 585 nm. Fluorescence
was not observed in control experiments using a non IAP protein, NusB/E
(see Fig. S2, ESI†).
Fig. 3 Identification of cyclononylprodigiosin (1) from the FC resin bound
fraction of the BRA 177 extract. (a) A 1H NMR spectrum (600 MHz)
collected from the survivin bound fraction in 35 mL of CDCl3. (b) A
1H NMR spectrum collected from pure 1 in CDCl3. Peaks from 1 are
assigned by number. * denotes peaks that were not from 1.
Fig. 4 Identification of prodigiosin (2) from the FC resin bound fraction
of the Xestospongia testudinaria X0192 fraction. (a) A 1H NMR spectrum
(500 MHz) of the X. testudinaria fraction in CDCl3. (inset) Expanded region
showing the NMR spectrum from 2 (blue) as compared to the X0192
fraction (black). (b) A 1H NMR spectrum (600 MHz) collected from the FC
resin fraction containing 2 in 35 mL of CDCl3. Peaks from 2 are assigned
numerically.
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for 1 and lex 534 nm and lem 555 nm for 2. However, we found
that 2 exhibited a decay in fluorescence intensity once in
solution (Fig. 5b and c). To ensure that this change in fluores-
cence did not interfere with the binding assay, the solution was
left to equilibrate for 3–4 h until the fluorescence intensity
stabilized. We next used Native-PAGE analysis to confirm the
selective binding of survivin when compared to a similarly sized
protein control, bromodomain 2 (BD2) of bromodomain con-
taining protein 4 (BRD4). In addition, we saw survivin staining
even when challenged with an E. coli lysate (Fig. S3, ESI†).
When survivin was added to 5 mM of 2 in assay buffer, the
fluorescence intensity increased significantly, without a spec-
tral shift (Fig. 5d). However, when the same amount of assay
buffer was added to 2, a decrease in fluorescence was found due
to dilution. This confirms that the increase in fluorescence
intensity of 2 is due to binding to survivin, hence the change in
the fluorescence properties of 2 can be used in a binding assay.
The full binding curve for 2 and survivin, as well as for the
buffer control, can be seen in Fig. 5e. A KD value of 11.5  3.1 mM
was determined by fitting the fluorescence data with a 1 : 1
binding model, describing complex formation as a function of
total survivin concentration. The same assay was repeated on 1,
with a KD value of 148.6  8.3 mM (Fig. 5f).
Finally, we performed a competition binding experiment of
5 mM of 2 and 50 mM AKER, a peptide known to bind at the BIR
domain of survivin.15 The resulting KD values in the presence
and absence of 50 mM AKER were almost the same (Fig. 5g)
indicating that 2 and AKER bind survivin independently, with
no overlap of their binding sites. Such outcome produces a
rather exciting proof of concept, while potentially revealing a
new binding pocket for this IAP.
Conclusions
This study demonstrates that a combination of a resin based
CONA screen (Fig. 1 and 2) with FC enrichment/isolation (Fig. 3
and 4) returned two members of the prodiginine family of
natural products from two distinct extracts as survivin binders.
The spectral properties of prodigiosin (2) have a fascinating
history as biological markers in the development of germ
warfare and play a potential role in religious observations
(bleeding statues and bread).16 Recent studies have shown
that prodigiosin’s fluorescence is environmentally sensitive,
responding to DNA17 and protein18 binding. An elegant appli-
cation of this method was recently demonstrated for the in situ
quantification of prodigiosin biosynthesis.19
It is relevant to mention that survivin up regulation renders
cells resistant to prodigiosin and, moreover, that prodigiosin
and other prodiginine pigments have been shown to decrease
expression of survivin (and other IAPs) in various human
cancer cell lines.20 In fact, prodigiosin (2) was able to resensi-
tize breast carcinoma cells to paclitaxel which, in turn, up
regulates survivin making cells resistant to apoptosis.21 Our
data strengthen the evidence on the central role undertaken by
survivin in triggering the apoptotic process induced by 2,22
potentially by directly targeting survivin.
Whilst prodigiosin (2) does not contain moieties which alert
PAINS concerns, the presence of pyrroles of which there are
three, does receive a special mention by Baell noting the
hydrolysis of pyrrole containing compounds.23 Whilst often
unstable due to polymerization to polypyrroles,24 the literature
does allude to diverse biological activities for pyrrole containing
compounds, such as antimicrobial, anti-viral, anti-malarial,
anti-convulsant, anti-inflammatory, antipsychotic, anti-
hypertensive, and finally anticancer agents.25 Additionally, a
highly-substituted pyrrole moiety is also found in the approved
drug atorvastatin (Lipitor). Using predicted oral-bioavailability
as a measure of drug-likeness, the data suggests that 2 is a
drug-like molecule for nearly all criteria;26 solubility: 56 mM,
lipophilicity: log P 4.16, molecular weight: 323.43 g mol1,
polarity: 53.17 Å2 TPSA, flexibility: 7 rotatable bonds. The
medical utility of this class is currently being explored through
clinical trials on prodigiosin.27
Furthermore, the fact that prodiginines were found in two of
the extracts, a microbial strain14 and a sponge known to
contain prodiginines,28 suggests that mining the natural and
synthetic diversity of this class could translate into probes for
screening applications for survivin and related IAPs.29 Overall,
this two-resin screening and enrichment approach, CONA–FC,
provides a practical and cost-effective advance towards the
Fig. 5 Spectral properties of prodigiosin 2. (a) Fluorescence excitation
and emission spectra of 2 in 20 mM HEPES, 100 mM NaCl, pH 7.5, 2%
DMSO. (b and c) Reduction of fluorescence emission of 2 in the above
buffer versus time passed from preparation of the solution. (d) The change
in fluorescence emission intensity of 2 in the presence of His6-survivin.
(e) The binding experiment of 5 mM of 2 and His6-survivin yielded a KD
value of 11.5  3.2 mM. (f) The comparison of the dissociation constant KD
value of 1 and 2 with survivin. (g) The competition of 2 and a BIR domain
ligand AKER (see ESI†).
Communication RSC Chemical Biology
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 2
7 
N
ov
em
be
r 
20
20
. D
ow
nl
oa
de
d 
on
 1
2/
15
/2
02
0 
12
:2
2:
46
 P
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
This journal is©The Royal Society of Chemistry 2020 RSC Chem. Biol.
identification of new fluorescent probes from diverse natural
resources.
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